Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.

被引：0
|
作者：
Patel, Urvi
Oluwole, Olalekan O.
Kassim, Adetola
Jayani, Reena
Belliveau, Paul
Savani, Bipin
Dholaria, Bhagirathbhai R.
机构：
[1] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Massachusetts Coll Pharm & Hlth Sci, Worcester, MA USA
[4] Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20049
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma
    Larrayoz, Marta
    Bjorklund, Chad Chad
    Jimenez, Maddalen
    Lozano, Teresa
    Sanz, Sonia
    Arriazu, Elena
    Zon, Rebecca
    Rodriguez-Madoz, Juan Roberto
    Paiva, Bruno
    Rodriguez-Otero, Paula
    San-Miguel, Jesus
    Prosper, Felipe
    Jose Lasarte, Juan
    Ebert, Benjamin
    Hagner, Patrick
    Martinez-Climent, Jose Angel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S6 - S7
  • [42] Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
    Song, J.
    Kim, G.
    Memon, R. S.
    Chi, K-Y.
    Chang, Y.
    Mehta, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S597 - S597
  • [43] Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
    Christopher J. Ferreri
    Michelle A. T. Hildebrandt
    Hamza Hashmi
    Leyla O. Shune
    Joseph P. McGuirk
    Douglas W. Sborov
    Charlotte B. Wagner
    M. Hakan Kocoglu
    Aaron Rapoport
    Shebli Atrash
    Peter M. Voorhees
    Jack Khouri
    Danai Dima
    Aimaz Afrough
    Gurbakhash Kaur
    Larry D. Anderson
    Gary Simmons
    James A. Davis
    Nilesh Kalariya
    Lauren C. Peres
    Yi Lin
    Murali Janakiram
    Omar Nadeem
    Melissa Alsina
    Frederick L. Locke
    Surbhi Sidana
    Doris K. Hansen
    Krina K. Patel
    Omar Alexis Castaneda Puglianini
    Blood Cancer Journal, 13
  • [44] Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
    Ferreri, Christopher J. J.
    Hildebrandt, Michelle A. T.
    Hashmi, Hamza
    Shune, Leyla O. O.
    McGuirk, Joseph P. P.
    Sborov, Douglas W. W.
    Wagner, Charlotte B. B.
    Kocoglu, M. Hakan
    Rapoport, Aaron
    Atrash, Shebli
    Voorhees, Peter M. M.
    Khouri, Jack
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Anderson, Larry D. D.
    Simmons, Gary
    Davis, James A. A.
    Kalariya, Nilesh
    Peres, Lauren C. C.
    Lin, Yi
    Janakiram, Murali
    Nadeem, Omar
    Alsina, Melissa
    Locke, Frederick L. L.
    Sidana, Surbhi
    Hansen, Doris K. K.
    Patel, Krina K. K.
    Puglianini, Omar Alexis Castaneda
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [45] Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
    Graeter, Allison
    Alexis, Omar
    Puglianini, Castaneda
    Hansen, Doris K.
    Vazquez-Martinez, Mariola A.
    Blue, Brandon Jamaal
    Khadka, Sushmita
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara L.
    Locke, Frederick L.
    Nishihori, Taiga
    Shain, Kenneth H.
    Baz, Rachid C.
    Alsina, Melissa
    Grajales-Cruz, Ariel Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
    Sidana, Surbhi
    Hosoya, Hitomi
    Jensen, Alexandria
    Liu, Lawrence
    Goyal, Anmol
    Hovanky, Vanna
    Sahaf, Bita
    Bharadwaj, Sushma
    Latchford, Theresa
    Arai, Sally
    Leahy, Sheryl
    Mei, Matthew
    Budde, Lihua E.
    Muffly, Lori S.
    Frank, Matthew J.
    Dahiya, Saurabh
    Htut, Myo
    Miklos, David
    Janakiram, Murali
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [47] Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
    Surbhi Sidana
    Hitomi Hosoya
    Alexandria Jensen
    Lawrence Liu
    Anmol Goyal
    Vanna Hovanky
    Bita Sahaf
    Sushma Bharadwaj
    Theresa Latchford
    Sally Arai
    Sheryl Leahy
    Matthew Mei
    Lihua E. Budde
    Lori S. Muffly
    Matthew J. Frank
    Saurabh Dahiya
    Myo Htut
    David Miklos
    Murali Janakiram
    Blood Cancer Journal, 13
  • [48] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Roex, Gils
    Timmers, Marijke
    Wouters, Kristien
    Campillo-Davo, Diana
    Flumens, Donovan
    Schroyens, Wilfried
    Chu, Yiwei
    Berneman, Zwi N.
    Lion, Eva
    Luo, Feifei
    Anguille, Sebastien
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [49] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Gils Roex
    Marijke Timmers
    Kristien Wouters
    Diana Campillo-Davo
    Donovan Flumens
    Wilfried Schroyens
    Yiwei Chu
    Zwi N. Berneman
    Eva Lion
    Feifei Luo
    Sébastien Anguille
    Journal of Hematology & Oncology, 13
  • [50] Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
    Samur, Mehmet K.
    Fulciniti, Mariateresa
    Aktas-Samur, Anil
    Bazarbachi, Abdul Hamid
    Tai, Yu-Tzu
    Campbell, Timothy B.
    Petrocca, Fabio
    Hege, Kristen
    Kaiser, Shari
    Anderson, Kenneth
    Munshi, Nikhil C.
    BLOOD, 2020, 136
12345